| 1 |
Central Inspection Plan Using Risk Based Approach of r- DNA Manufacturing Units for the year- 2025 |
2025-Mar-05 |
|
532 KB |
| 2 |
List of new drugs (r-DNA origin)CT-21 approved for manufacture and marketing in India during Jan 2020 till Jan 2025 |
2025-Jan-24 |
|
718 KB |
| 3 |
List of new drugs (r-DNA origin) CT-18 approved for import and marketing in India during Jan 2020 till Jan 2025 |
2025-Jan-24 |
|
780 KB |
| 4 |
Import and market permission till 2019 |
2024-Jul-18 |
|
1107 KB |
| 5 |
Central Inspection Plan Using Risk Based Approach of r- DNA Manufacturing Units for the year- 2024 |
2024-Jan-31 |
|
756 KB |
| 6 |
CT permission issued for r-DNA derived drugs for the year 2020 |
2020-Nov-11 |
|
85 KB |
| 7 |
CT permission issued for r-DNA derived drugs for the year 2019 |
2020-Nov-10 |
|
88 KB |
| 8 |
Permissions granted in Form 46/46 A |
2020-Feb-03 |
|
776 KB |
| 9 |
List of rDNA Clinical trials to be Inspected as per the Central Inspection Plan-2019 |
2019-May-17 |
|
85 KB |
| 10 |
Central Inspection Plan Using Risk Based Approach of r-DNA products Manufacturing Units for 2019 QA-INS-012 |
2019-May-16 |
|
2815 KB |
